Flyer

Annals of Clinical and Laboratory Research

  • ISSN: 2386-5180
  • Journal h-index: 19
  • Journal CiteScore: 5.42
  • Journal Impact Factor: 4.64
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Directory of Research Journal Indexing (DRJI)
  • Publons
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • Zenodo
Share This Page

Atherosclerotic changes in patients with obstructive sleep apnea

4th Edition of International Conference on Clinical Chemistry & Molecular Diagnostics
April 15-16, 2019 | Paris, France

Victor Manolov, Georgiev O, Vasilev V, Pencheva Genova V,Grozdanova R, Traykov L, Petrova I, Tzatchev K, Hadjidekova S, Karadjova M, Voleva S, Nikolova M, Angov G, Petrova Ivanova I, Kunchev T, Ovcharov D, Gramatikova Z

Dept. of Clinical Laboratory and Clinical Immunology, Medical University, Bulgaria Dept. of Propedeutics of Internal Diseases, Medical University Sofia Clinical laboratory and clinical pharmacology, University Aleksandrovska hospital Sofia, Bulgaria NCIP, Bulgaria Department of Neurology, Medical University Sofia Dept. of Medical Genetics, Medical University Sofia NCIPD, Sofia RED Laboratories N V/SA, Belgium

Posters & Accepted Abstracts: Ann Clin Lab Res

Abstract:

Obstructive sleep apnea syndrome (OSA) is defined as a combination of symptoms as a result of intermittent, recurrent constraint and / or complete airway overhead airway overflow (sleep disturbance). During desaturation episodes, the organism is subjected to chronic stress. This leads to reduced nitric oxide secretion, increased release of interleukin-6, tumour necrosis factor-alpha and other pro-inflammatory cytokines. The described pathological cascades are associated with the development of insulin resistance, arterial hypertension, metabolic syndrome, systemic atherosclerosis and increased cardiovascular risk. 47 patients aged 43.1±7.7 with OSA were included in this study. Their results were compared to sex and age matched healthy control. CBC, serum iron, ferritin, hsCRP, hepcidin, homocysteine and vitamin B12 were measured in the included groups. IMT and FMT were used for atherosclerotic changes evaluation. We found increased serum hepcidin levels in OSA patients with IMT and FMD changes (99.8±14.5 μg/L) compared to healthy controls (19.7±1.9 μg/L); P<0.001. IMT and FMD correlates positive in OSA patients with atherosclerotic changes to serum hepcidin concentrations (r=0.811, r=0.847, resp.; P<0.01). Serum hepcidin correlates positively to homocysteine and hsCRP in OSA patients (r=0.788, r=0.797, resp.; P<0.005).Brain-vascular disease risk factors are connected to obstructive sleep apnea syndrome. Disregulation of iron homeostasis is one of the main risk atherogenesis factors. Early hepcidin quantification might predict an atherosclerosis occurrence in OSA patients, which might be very important for better clinical diagnosis and practice.

Biography :

E-mail: victhedoc4@abv.bg